15 October 2007
Munich, Germany – Affectis Pharmaceuticals AG, a biopharmaceutical company developing novel drugs for depression and schizophrenia, today announced the start of a clinical Phase II trial to study the efficacy and safety of Cimicoxib as a treatment for depression. The first patient has been enrolled at the Clinic of Psychiatry and Psychotherapy at the Ludwig-Maximilians-University in Munich. This double-blind, randomised, placebo controlled study will include a total of 134 patients and is being conducted at multiple centres in Germany. The primary endpoint of the study is a clinically relevant improvement in the Hamilton Depression Rating Scale.
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. Affectis in-licensed Cimicoxib from Palau Pharma in early 2007. Cimicoxib is characterised by a good safety profile as demonstrated in 5 clinical studies in which a total of 261 subjects received the drug. The compound also showed efficacy at 3 doses in a Phase II study in post-operative pain conducted by Palau.
| File | File size |
|---|---|
 10-2007 Clinical Study E.pdf | 25 Kb |
05 March 2007
Munich, Germany, -- Affectis Pharmaceuticals AG announced today that it has extended its research collaboration with Mitsubishi Pharma. The collaboration, established in February 2005, called for Affectis to use its expertise to assist Mitsubishi in developing novel therapeutics for the treatment of affective disorders and has now been expanded by another project.
| File | File size |
|---|---|
| 03-2007 Affectis - Mitsubishi Pharma engl.pdf | 23 Kb |
01 March 2007
Toronto, Ontario, – Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Contract Services Agreement with Affectis Pharmaceuticals AG, of Munich, Germany. Affectis has contracted Dalton for the manufacturing of preclinical tox material with potential for cGMP production. Affectis is an exciting addition to Dalton’s portfolio of world wide clients. Dalton has first hand experience advancing compounds from a range of therapeutic areas including Alzheimer’s, cardiovascular diseases, HIV, anti-aging and now also affective disorders.
| File | File size |
|---|---|
| 03-2007 Dalton Affectis engl.pdf | 60 Kb |
Copyright © 2010 Affectis Pharmaceuticals AG. All Rights Reserved.
